Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Monday, August 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab and argenx have reported positive topline results from the Phase 3 ALKIVIA trial of efgartigimod in adults with autoimmune myositis. The study successfully met its primary endpoint, demonstrating statistical significance in the combined population of immune-mediated necrotizing myopathy and dermatomyositis. This outcome highlights the potential of efgartigimod as a treatment option.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive topline results from the Phase 3 ALKIVIA trial.
  • Study met its primary endpoint with statistical significance.
  • Efgartigimod shows promise for treating autoimmune myositis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
6.4%
average across 6 past catalysts
Cash runway
~24 mo
Low dilution risk
Lead asset
ZL-3101
Phase 2 · Eczema

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod dem

Frequently Asked Questions

What were the results of the ALKIVIA trial?

The ALKIVIA trial reported positive topline results, meeting its primary endpoint.

What is efgartigimod used for?

Efgartigimod is being evaluated for treating autoimmune myositis.

Which companies are involved in the ALKIVIA trial?

Zai Lab and argenx are the companies conducting the ALKIVIA trial.

What conditions were included in the trial?

The trial included patients with immune-mediated necrotizing myopathy and dermatomyositis.

ShareAdd on Google
Tags: ZLAB Viatris Investor Conferences Healthcare Zai Lab argenx efgartigimod autoimmune myositis ALKIVIA trial
Last updated: Aug 17, 2026

Biotech snapshot

Cash runway
$618M liquidity · $25M/mo burn
~24 mo
Low dilution risk
Lead asset
ZL-3101Phase 2
Eczema →

Catalyst track record

+60%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →